Cytokines as therapeutic targets for the gastrointestinal manifestations of scleroderma

Canadian Journal of Gastroenterology

Volumn 18, Issue 1, 2004, Pages 22-24

  Raoul, Jennifer M ^a   Verma, Monica ^a   Tan, Ernest ^a   Peterson, Theresa C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

CTGF; Cytokines; G1 dysfunction; IL 4; IL 6; MCP 1; PDGF; Scleroderma; TGF

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; ESOPHAGUS DISEASE; FIBROBLAST; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE SYSTEM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCLERODERMA;

EID: 1442301648     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/458271     Document Type: Review

References (52)

1. Generini S, Fiori G, Moggi Pignone A, Matucci Cerinic M, Cagnoni M. Systemic sclerosis: A clinical overview. Adv Exp Biol Med (RheumaDerm) 1999;455:73-83.
2. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastro Clin North Am 1998;27:563-93.
3. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265-82.
4. Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997;92:763-71.
5. Sapadin AN, Esser AC, Fleischmajer R. Immunopathogenesis of scleroderma: Evolving concepts. Mt Sinai J Med 2001;68:233-42.
6. Chizzolini C, Raschi E, Rezzonico R, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002;46:1602-13.
7. Okano Y. Antinuclear antibodies in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996;22:709-35.
8. Ingregnoli F, Trabattoni D, Saresella M, Fantini F, Clerici M. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 2003;108:21-8.
9. Black CM. The treatment of scleroderma. Adv Exp Biol Med (RheumaDerm) 1999;455:271-7.
10. Fagundus MD, Leroy EC. Cytokines and systemic sclerosis. Clin Dermatol 1994;12:407-17.
11. Simms RW, Korn JH. Cytokine directed therapy in scleroderma: Rationale, current status, and the future. Curr Opin Rheumatol 2002;14:717-22.
12. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
13. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: Implication in fibrosis. Exp Biol Med 2002;227:301-14.
14. Moses HL, Coffey RJ, Loef EB, Lyons RM, Keski-Oja J. Transforming growth factor beta regulation of cell proliferation. J Cell Biol 1987;5(Suppl):1-7.
15. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. TGF-β - A role in systemic sclerosis? J Pathol 1998;184:4-6.
16. Helman S, Cotton SA, Jayson MIV, Hoyland J, Herrick A, Freemont AJ. Microvascular abnormality and TGF-β in systemic sclerosis skin. Br J Rheumatol 1997;36(Suppl 1):30(54A).
17. Yamane K, Ihn H, Kubo M, Tamaki K. Increased transcriptional activities of transforming growth factor β receptors in scleroderma fibroblasts. Arthritis Rheum 2002;46:2421-8.
18. Dong C, Zhu S, Wang T, et al. Deficient smad7 expression: A putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908-13.
19. Yamamoto T, Nishioka K. Analysis of the effect of halofuginone on bleomycin-induced fibrosis. Rheumatology 2002;41:594-6.
20. Levi-Schaffer F, Nagler A, Slavin Sknopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone. J Clin Invest 1996;106:84-8.
21. Pines N, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003;9:417-25.
22. McGaha TL, Phleps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type I collagen synthesis and skin sclerosis, blocks TGF-β mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-70.
23. McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA. Halofuginone inhibition of COL1A2 promoter activity via a c-jun-dependent mechanism. Arthritis Rheum 2002;46:2748-61.
24. Shi-wen X, Pennington D, Holmes A, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000;259:213-24.
25. Stratton R, Shi-wen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-50.
26. Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996;106:723-33.
27. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with scleroderma. J Invest Dermatol 1995;105:280-4.
28. Stratton R, Rajkumar V, Ponticos M, et al. Prostacyclin derivatives prevent the fibrotic response to TGF-β by inhibiting the Ras/MEK/ERK pathway. FASEB J 2002;16:1949-51.
29. Isbrucker RA, Peterson TC. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol Appl Pharmacol 1998;149:120-6.
30. Zheng XY, Zhang JZ, Tu P, Ma SQ. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 1998;18:90-7.
31. Klareskog L, Gustafsson R, Scheynius A, et al. Increased expression of plasma platelet-derived growth factor type β receptors in systemic sclerosis. Arthritis Rheum 1990;33:1534-41.
32. Takemura H, Suzuki H, Fujisawa H, et al. Enhanced interleukin-6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet-derived growth factor. J Rheumatol 1998;25:1534-9.
33. Peterson TC, Isbrucker R, Hooper ML. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology 1994;28:259-70.
34. Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma, and morphoea skin and their production of collagen, glycosaminoglycan, and fibronectin. Br J Dermatol 1990;123:339-46.
35. Peterson TC. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 1993;17:486-93.
36. Peterson TC, Peterson MR, Robertson HA, During M, Dragunow M. Selective down-regulation of c-jun gene expression by pentoxifylline and c-jun anti-sense interrupts platelet-derived growth factor signaling: Pentoxifylline inhibits phosphorylation of c-Jun on serine 73. Mol Pharmacol 2002;61:1476-88.
37. Tsuji-Yamada J, Nakazawa M, Minami M, Sasaki T. Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 2001;28:1252-8.
38. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest 1992;90:1479-85.
39. Jimenez SA, Millan A, Bashey RI. Scleroderma-like alterations in collagen metabolism occurring in the TSK (tight skin) mouse. Arthritis Rheum 1984;27:180-5.
40. Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 1996;107:856-9.
41. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998;28:2619-29.
42. Ong CJ, Ip S, Teh SJ, et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999;196:60-8.
43. Tepper RI, Levinson DA, Stanger BZ, Campos-Torres J, Abbas A, Leder P. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1990;62:457-67.
44. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin 6 and interleukin 10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
45. Feghali CA, Bost KL, Boulware DW, Levy LS. Control of IL-6 expression and response to fibroblasts from patients with systemic sclerosis. Autoimmunity 1994;17:309-18.
46. Filaci G, Cutolo M, Scudeletti M, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 1999;38:992-6.
47. Tsuji-Yamada J, Nakazaw M, Takahashi K, et al. Effect of IL-12 encoding plasmid administration on tight-skin mouse. Biochem Biophys Res Comm 2001;280:707-12.
48. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1999;11:97-101.
49. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001;26:133-9.
50. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65.
51. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998;114:293-300.
52. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088-98.